Short answer
Foghorn Therapeutics Inc. (FHTX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $16M (up 112.7% year over year) with net income of −$7M.
Q2 2026 key financials · XBRL
- Revenue
- $16M
- +112.7% YoY · +391.9% QoQ
- Net income
- −$7M
- +59.9% YoY · +63.8% QoQ
- Operating margin
- -54.8%
- EPS (diluted)
- −$0.10
- +64.3% YoY · +65.5% QoQ
Source: XBRL data from the Foghorn Therapeutics Inc. (FHTX) Q2 2026 10-Q on SEC EDGAR. USD.
Foghorn Therapeutics Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $16.1M, up $8.5M YoY from $7.6M
- Net loss $7.2M versus $17.9M YoY; operating loss $8.8M versus $21.1M
- Best-performing revenue line: Lilly collaboration, driven by $14.2M cumulative catch-up adjustment
- R&D expense $18.5M, down $3.3M YoY; Lilly partnered programs declined $4.4M
- January 2026 offering generated $50.0M gross proceeds; additional funding required for ongoing operations
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- No newly added risk factor or quarter-specific trigger disclosed
- No regulatory, legal, or compliance risk updates disclosed
- No operational, competitive, market, liquidity, debt, currency, or concentration risk updates disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Foghorn Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.